The stock will trade on the MIRACLE trial unblinding in June 2026, not on quarterly financials. The EPS miss is severe but typical for pre-revenue biotechs. Watch for the 45-subject data release — a positive readout could be transformative; a negative one would likely be catastrophic given the $12M market cap and limited cash runway.
Price Chart
Executive Summary
Moleculin Biotech reported Q1 2026 net loss of $12.8M ($3.54/share) vs $5.9M loss a year ago, with zero revenue. The EPS of -$3.54 is a significant miss vs consensus of -$1.46. However, the stock is driven by clinical catalysts: MIRACLE trial enrollment surpassed 45 subjects with a 40% composite complete remission rate, and first interim unblinding is expected in June 2026. Cash of $10.3M supports operations into Q3 2026, but the company will need additional financing soon.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $12.8M vs $5.9M loss in Q1 2025; EPS -$3.54 vs consensus -$1.46 (miss)
- Zero revenue; pre-revenue clinical-stage biotech
- Cash and cash equivalents $10.3M as of March 31, 2026; management expects runway into Q3 2026
- MIRACLE trial enrolled 45 subjects; blinded 40% composite complete remission rate observed
- First interim unblinding of 45-subject data expected in June 2026
- Raised ~$8.3M in gross proceeds during Q1 2026 via financing transactions
- R&D expenses increased to $5.4M from $3.4M, driven by MIRACLE trial costs in Europe
Financial Impact
Net loss widened to $12.8M from $5.9M; EPS -$3.54 vs consensus -$1.46; cash burn rate ~$2.6M/month
Risk Factors
- Cash runway only into Q3 2026; dilutive financing likely needed
- MIRACLE trial unblinding in June 2026 is binary — failure would severely impair the stock
- Zero revenue; entirely dependent on clinical success and capital markets
- EPS miss of 142% vs consensus reflects worsening operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295836 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 16d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 | awaiting T+20 | — | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers